宫颈癌磁共振图像引导近距离放疗3次与4次分次的临床结局比较
该回顾性研究纳入241例2018年FIGO分期IB至IVA期宫颈癌患者,比较24 Gy/3次与28 Gy/4次磁共振图像引导近距离放疗的疾病与毒性结局。中位随访3.2年,两组3年无病生存率、局部失败、远处失败、G2+胃肠道及阴道毒性均无显著差异,24 Gy/3次组3年累积G2+泌尿毒性较低(9% vs 23%,P=0.03)。作者认为24 Gy/3次是28 Gy/4次的安全替代方案。
要点
- 24 Gy/3次与28 Gy/4次组3年无病生存率分别为77%与68%,无显著差异(P=0.21)。
- 24 Gy/3次组3年累积G2+泌尿毒性为9%,低于28 Gy/4次组的23%(P=0.03)。
- 两组局部失败、远处失败、G2+胃肠道及阴道毒性均无显著差异。
核心结论
- 宫颈癌患者接受24 Gy/3次与28 Gy/4次磁共振图像引导近距离放疗的无病生存率、局部失败、远处失败、胃肠道及阴道毒性相似,24 Gy/3次组G2+泌尿毒性有降低趋势。
- 作者认为24 Gy/3次这一资源需求较低的近距离放疗分次方案是28 Gy/4次用于宫颈癌根治性治疗的安全替代方案。
研究设计与样本
- 回顾性研究,纳入2014年4月至2021年3月间接受根治性放化疗的241例连续宫颈癌患者,FIGO 2018分期IB至IVA期。
- 42%患者接受24 Gy/3次,58%接受28 Gy/4次。
- 采用Kaplan-Meier法估计无病生存率并用log-rank检验比较;采用累积发生率函数并以死亡为竞争风险估计局部失败、远处失败及G2+胃肠道、泌尿和阴道毒性累积发生率,并用Gray检验比较。
主要发现
- 中位随访3.2年(范围0.2-9.2年),63例(26%)患者共发生14例局部失败、41例区域淋巴结失败和51例远处失败。
- 24 Gy/3次组与28 Gy/4次组3年无病生存率分别为77%与68%,无显著差异(P=0.21)。
- 24 Gy/3次组与28 Gy/4次组3年累积局部失败率分别为5%与7%(P=0.57),远处失败率分别为22%与25%(P=0.86)。
- 24 Gy/3次组与28 Gy/4次组3年累积G2+胃肠道毒性分别为11%与20%(P=0.13),G2+阴道毒性分别为14%与17%(P=0.48)。
- 24 Gy/3次组3年累积G2+泌尿毒性为9%,低于28 Gy/4次组的23%(P=0.03)。
临床怎么用
- 作者认为对于宫颈癌根治性治疗,24 Gy/3次这一资源需求较低的近距离放疗分次方案是28 Gy/4次的安全替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Magnetic resonance image-guided brachytherapy is essential in the management of locally advanced cervical cancer. This study compares disease and toxicity outcomes in cervical cancer patients treated with 24 Gy/3 fractions (Fr) versus the conventional 28 Gy/4 Fr. METHODS AND MATERIALS: This retrospective study included 241 consecutive patients with International Federation of Gynecology and Obstetrics 2018 stage IB to IVA cervical cancer treated with definitive chemoradiation between April 2014 and March 2021. Disease-free survival (DFS) was estimated using the Kaplan-Meier method and compared using the log-rank test. Cumulative incidence of local failure (LF), distant failure (DF), and G2+ gastrointestinal (GI), urinary and vaginal toxicity were estimated using the cumulative incidence function with death as a competing risk and compared using Gray's test. RESULTS: Of the 241 patients, 42% received 24 Gy/3 Fr and 58% received 28 Gy/4 Fr. With a median follow-up of 3.2 (range, 0.2-9.2) years, there were 14 local, 41 regional nodal, and 51 distant failures in 63 (26%) patients. No significant differences were found between the 24 Gy/3 Fr and 28 Gy/4 Fr groups in 3-year DFS (77% vs 68%, P = .21), the 3-year cumulative incidence of LF (5% vs 7%, P = .57), DF (22% vs 25%, P = .86), G2+ GI toxicity (11% vs 20%, P = .13), or G2+ vaginal toxicity (14% vs 17%, P = .48), respectively. The 3-year cumulative G2+ urinary toxicity rate was lower in the 24 Gy/3 Fr group (9% vs 23%, P = .03). CONCLUSIONS: Patients with cervical cancer treated with 24 Gy/3 Fr had similar DFS, LF, DF, GI, and vaginal toxicity rates and a trend toward a lower G2+ urinary toxicity rate compared with those treated with 28 Gy/4 Fr. A less resource-intensive brachytherapy fractionation schedule of 24 Gy/3 Fr is a safe alternative to 28 Gy/4 Fr for definitive treatment of cervical cancer.
引用
- Chuk E, Yu C, Scott AA, et al. Clinical Outcomes of 3 Versus 4 Fractions of Magnetic Resonance Image-Guided Brachytherapy in Cervical Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 38936633. doi:10.1016/j.ijrobp.2024.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。